Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Fes CRISPR/Cas9 KO Plasmid (h): sc-403246
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Fes CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Fes genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Fes Antibody (D-9): sc-377179
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fes CRISPR/Cas9 KO Plasmid (h) | sc-403246 | 20 µg | $397.00 |
Overview
FES encodes Fes, a non-receptor cytoplasmic tyrosine kinase expressed primarily in hematopoietic and myeloid lineages where it couples receptor inputs to downstream phosphorylation cascades. Fes participates in signaling networks that regulate differentiation, cytoskeletal remodeling, cell adhesion, and innate immune functions, integrating cues from cytokine and growth factor pathways. Through its SH2 and kinase domains, Fes modulates substrates involved in actin dynamics and transcriptional programs that shape leukocyte development and inflammatory responses. Dysregulated FES signaling and expression have been investigated in hematologic malignancy biology and in contexts of aberrant myeloid activation, making it a relevant node for dissecting kinase-driven signaling circuitry.
Fes CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FES gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FES together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FES open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Fes protein expression.
This CRISPR knockout system enables efficient generation of FES-deficient cell models for investigation of Fes signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FES exon(s) critical for Fes function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FES genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Fes CRISPR/Cas9 KO Plasmid (h) and Fes CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FES locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Fes HDR Plasmid (h) and Fes HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FES homology arms to support homology-directed repair at defined FES target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.